Maraviroc: a review of its use in HIV infection and beyond
SM Woollard, GD Kanmogne - Drug design, development and …, 2015 - Taylor & Francis
The human immunodeficiency virus-1 (HIV-1) enters target cells by binding its envelope
glycoprotein gp120 to the CD4 receptor and/or coreceptors such as CC chemokine receptor …
glycoprotein gp120 to the CD4 receptor and/or coreceptors such as CC chemokine receptor …
Translational research in infectious disease: current paradigms and challenges ahead
JM Fontana, E Alexander, M Salvatore - Translational Research, 2012 - Elsevier
In recent years, the biomedical community has witnessed a rapid scientific and technologic
evolution after the development and refinement of high-throughput methodologies …
evolution after the development and refinement of high-throughput methodologies …
A new tool for the paediatric HIV research: general data from the Cohort of the Spanish Paediatric HIV Network (CoRISpe)
MI de Jose, S Jiménez de Ory, M Espiau… - BMC infectious …, 2013 - Springer
There are approximately from 1,100 to 1,200 HIV-infected children in a follow-up in Spain. In
2008 an open, multicentral, retrospective and prospective Cohort of the Spanish Paediatric …
2008 an open, multicentral, retrospective and prospective Cohort of the Spanish Paediatric …
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping
MCF Prosperi, L Bracciale, M Fabbiani… - Retrovirology, 2010 - Springer
Background Trofile® is the prospectively validated HIV-1 tropism assay. Its use is limited by
high costs, long turn-around time, and inability to test patients with very low or undetectable …
high costs, long turn-around time, and inability to test patients with very low or undetectable …
Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition
HIV-1 entry begins with viral envelope glycoprotein gp120 interacting with host-cell CD4 and
an entry coreceptor (mainly chemokine receptors CCR5 or CXCR4). Inhibitors of particular …
an entry coreceptor (mainly chemokine receptors CCR5 or CXCR4). Inhibitors of particular …
Clinical utility of maraviroc
J Parra, J Portilla, F Pulido… - Clinical drug …, 2011 - Springer
Maraviroc belongs to the family of chemokine (CC motif) receptor 5 (CCR5) antagonists that
prevent the entry of human immunodeficiency virus (HIV) into host CD4+ T cells by blocking …
prevent the entry of human immunodeficiency virus (HIV) into host CD4+ T cells by blocking …
Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti–HIV-1 Antibodies
MH Pahus, Y Zheng, M Olefsky, JD Gunst… - The Journal of …, 2024 - academic.oup.com
Background Development of a screening assay for the clinical use of broadly neutralizing
antibodies (bnAbs) is a priority for HIV therapy and cure initiatives. Methods We assessed …
antibodies (bnAbs) is a priority for HIV therapy and cure initiatives. Methods We assessed …
Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects
MM Pozo-Balado, M Martínez-Bonet… - The Journal of …, 2014 - academic.oup.com
Background. Maraviroc is the first antiretroviral (ART) drug to target a human protein, the
CCR5 coreceptor; however, the mechanisms of maraviroc-associated immunomodulation in …
CCR5 coreceptor; however, the mechanisms of maraviroc-associated immunomodulation in …
TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches
A Gonzalez-Serna, M Leal, M Genebat… - Journal of clinical …, 2010 - Am Soc Microbiol
The only clinically validated assay available to determine HIV tropism is Trofile, an assay
that possesses some limitations. Our first aim was to develop a new phenotypic tropism test …
that possesses some limitations. Our first aim was to develop a new phenotypic tropism test …
Effect of maraviroc on HIV disease progression-related biomarkers
MC Romero-Sánchez, K Machmach… - Antimicrobial agents …, 2012 - Am Soc Microbiol
The potential effect of blocking the CCR5 receptor on HIV disease progression biomarkers is
not well understood. We showed that an 8-day maraviroc (MVC) monotherapy clinical test …
not well understood. We showed that an 8-day maraviroc (MVC) monotherapy clinical test …